Business Model Breakdown
How Dexcom Inc Makes Money
DXCM
Market Cap
$23.8B
Annual Revenue
$4.7B
Profit Margin
17.9%
Employees
10,200
The Short Version
Dexcom Inc. operates as a medical technology company specializing in continuous glucose monitoring (CGM) systems for individuals with diabetes. The core business model revolves around selling integrated systems composed of disposable sensors, reusable transmitters, and display devices (or smartphone integration). Revenue is primarily generated from the recurring sales of its high-margin disposable sensors, which patients replace regularly, establishing a robust, subscription-like revenue stream. The company's customer base includes both Type 1 and Type 2 diabetes patients, supported by healthcare providers.
Where the Revenue Comes From
Sales of disposable CGM sensors (~80-90% of revenue)
Sales of reusable CGM transmitters (~10-20% of revenue)
Who buys: Individuals with Type 1 and Type 2 diabetes (both insulin and non-insulin dependent), healthcare providers, and integrated health networks.
Why It Works (Competitive Advantages)
- ✔Proprietary technology and continuous innovation (G7, Stelo)
- ✔Strong brand recognition and patient loyalty
- ✔Robust regulatory expertise and established market access channels
- ✔Extensive R&D pipeline to maintain technological leadership
Economic Moat: Narrow (Intangible Assets/IP, Switching Costs, Brand Power)
What Our Analysis Says
DVR Score as of April 26, 2026
Dexcom maintains its strong position as a Continuous Glucose Monitoring (CGM) market leader, driven by successful G7 global rollout and promising initial penetration of Stelo into the Type 2 non-insulin market. The company exhibits solid financial health, consistent operational execution (Q4 2025 earnings beat), and positive analyst sentiment with recent upgrades. The absence of previous concerns regarding a fiduciary duties investigation, as confirmed by current real-time intelligence, improves its risk profile. However, achieving a 10x return within 3-5 years from its current large-cap valuation of $23.76B (requiring a jump to over $237B) remains a highly ambitious target, demanding hyper-growth rates beyond its current 13.1% YoY revenue growth. The score reflects a high-quality company with significant organic growth and an improved risk profile, but a modest probability for such an extreme return.